Mark Micolucci, MD
Family Medicine · Travelers Rest, SCNPI 1336633114
Payments from drug & device makers
Across 266 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$669
- Novo Nordisk$604
- Pfizer$325
- Lilly USA, LLC$312
- AstraZeneca$283
- GSK$272
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,060100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $669 |
| Novo Nordisk | 40 | $604 |
| Pfizer | 19 | $325 |
| Lilly USA, LLC | 20 | $312 |
| AstraZeneca | 15 | $283 |
| GSK | 17 | $272 |
| Dexcom, Inc. | 16 | $269 |
| Boehringer Ingelheim | 12 | $182 |
| Amgen | 10 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Bayer | 7 | $100 |
| Abbott | 4 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Exact Sciences | 6 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Novartis | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Upsher-smith Laboratories LLC | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Renalytix AI, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$4,060 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $131,168 |
| OzempicSemaglutide | 77 | $106,677 |
| JardianceEmpagliflozin | 66 | $86,406 |
| MounjaroTirzepatide | 40 | $47,441 |
| XareltoRivaroxaban | 44 | $45,284 |
| FarxigaDapagliflozin Propanediol | 54 | $40,826 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $39,790 |
| TrulicityDulaglutide | 22 | $31,038 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $21,137 |
| Repatha SureclickEvolocumab | 25 | $20,945 |
| RybelsusSemaglutide | 13 | $19,620 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,707 |
| Novolog FlexpenInsulin Aspart | 37 | $12,000 |
| MyrbetriqMirabegron | 17 | $11,762 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $325 | $131,168115 claims |
| Novo NordiskOzempic, Rybelsus | $604 | $126,29790 claims |
| Boehringer IngelheimJardiance | $182 | $86,40666 claims |
| Lilly USA, LLCMounjaro, Trulicity | $312 | $78,47962 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $272 | $64,65692 claims |
| AstraZenecaFarxiga | $283 | $40,82654 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $18 | $21,13718 claims |
| AbbVieSynthroid | $669 | $3,90263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Travelers Rest
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.